<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, May 9, 2019 (HealthDay News) — A new test can predict the course of inflammatory bowel disease (IBD) in patients, according to a study published online April 27 in Gut<\/i>.<\/p>\n
Daniele Biasci, Ph.D., from the University of Cambridge in the United Kingdom, and colleagues performed transcriptomic analyses on purified CD8 T cells and\/or whole blood from patients with active IBD. Consensus clustering of CD8 T cell transcriptomes was used to identify IBD1\/IBD2 patient subgroups. Machine learning identified groups of genes that could classify IBD1\/IBD2 subgroups. The best classifying genes were optimized for a quantitative polymerase chain reaction (qPCR) test that was validated in 66 patients with Crohn disease (CD) and 57 patients with ulcerative colitis (UC).<\/p>\n
The researchers found that in both validation cohorts, a 17-gene qPCR-based classifier organized patients into two distinct subgroups. Regardless of the underlying diagnosis, the poor-prognosis IBD1 subgroup (IBDhi patients) experienced significantly more aggressive disease than IBDlo patients (IBD2 subgroup). The IBDhi group needed earlier treatment escalation (hazard ratios, 2.65 [CD] and 3.12 [UC]) and more escalations over time. For multiple escalations within 18 months, the test yielded a sensitivity of 72.7 percent (CD) and 100 percent (UC) and a negative predictive value of 90.9 percent (CD) and 100 percent (UC).<\/p>\n
“This is the first validated prognostic biomarker that can predict prognosis in newly diagnosed patients with IBD and represents a step towards personalized therapy,” the authors write.<\/p>\n
Several authors disclosed financial ties to PredictImmune, which partially funded the study.<\/p>\n